Consequently, while it is still essential to explore the broader implications of the noncanonical activity of EZH2 in other cancer types, targeting the novel function of the EZH2–E2F1 complex, such as developing mutations to block their interaction, could provide a new therapeutic avenue for treating aggressive cancers resistant to current EZH2 inhibitors. Here, E2F1 is linked to cancer.